Summary: Elevated glycine levels are associated with the onset of psychosis, a new study reports.
A new study of young people experiencing a first episode of psychosis reports elevations in the brain chemicals glutamate and glycine. Published in Biological Psychiatry, the study led by Dr. Dost Öngür of Harvard Medical School provides the first ever measurement of glycine levels in patients with psychotic disorders.
Abnormal brain activity in psychotic disorders, such as schizophrenia and bipolar disorder, is thought to stem in part from impaired function of the NMDA receptor. Glutamate and glycine activate the receptor, which is an important mediator of brain signaling for processes such as learning and memory. According to Dr. Öngür, the findings may serve as a marker in the development of future treatments aimed at restoring function of NMDA receptors.
Reliable detection of glycine in the human brain has previously been very challenging–if not impossible–with conventional techniques, as an overlapping signal interferes with its detection. But first author Dr. Sang-Young Kim and colleagues applied a new method of the brain imaging technique called MR spectroscopy to suppress the interfering signal and reveal the hidden glycine signal.
Glycine levels were higher in 46 patients with first-episode psychosis, compared with 50 healthy participants. “Our findings suggest that glycine abnormalities may play a role in the earliest phases of psychotic disorders,” said Dr. Öngür. The researchers also measured increased glutamate levels in patients, which lines up with strong support for elevated glutamate reported in other studies of first-episode psychosis. The elevations in glutamate and glycine indicate that NMDA receptors receive abnormal stimulation in psychotic disorders.
The increased glycine level was the opposite of what the authors expected to find — researchers have actually tried raising glycine levels in patients to compensate for the underperforming NMDA receptors. The new findings revealing higher levels early on in the disease might help to explain why glycine supplementation hasn’t worked as well as researchers hoped.
“This study supports the notion of different developmental phases in the biology of schizophrenia. These phases might require somewhat different treatments,” said Dr. John Krystal, Editor of Biological Psychiatry.
About this neuroscience research article
Source: Rhiannon Bugno – Elsevier Image Source: NeuroscienceNews.com image is credited to RicHard-59 and is licensed CC BY SA 3.0. Original Research: Full open access research for “In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time–Averaged Proton Magnetic Resonance Spectroscopy at 4T” by Sang-Young Kim, Marc J. Kaufman, Bruce M. Cohen, J. Eric Jensen, Joseph T. Coyle, Fei Du, and Dost Öngür in Biological Psychiatry. Published online September 7 2017 doi:10.1016/j.biopsych.2017.08.022
Cite This NeuroscienceNews.com Article
[cbtabs][cbtab title=”MLA”]Elsevier “Research Identifies Brain Chemical Abnormalities in Earliest Stage of Psychosis.” NeuroscienceNews. NeuroscienceNews, 11 October 2017. <https://neurosciencenews.com/psychosis-brain-chemicals-7722/>.[/cbtab][cbtab title=”APA”]Elsevier (2017, October 11). Research Identifies Brain Chemical Abnormalities in Earliest Stage of Psychosis. NeuroscienceNews. Retrieved October 11, 2017 from https://neurosciencenews.com/psychosis-brain-chemicals-7722/[/cbtab][cbtab title=”Chicago”]Elsevier “Research Identifies Brain Chemical Abnormalities in Earliest Stage of Psychosis.” https://neurosciencenews.com/psychosis-brain-chemicals-7722/ (accessed October 11, 2017).[/cbtab][/cbtabs]
In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time–Averaged Proton Magnetic Resonance Spectroscopy at 4T
Background Accumulating evidence suggests the involvement of abnormal glutamateric neurotransmission and N-methyl-D-aspartate receptor hypofunction in the pathophysiology of psychotic disorders. The purpose of this study was to quantify in vivo glutamate (Glu) and glycine (Gly) levels in patients with first-episode psychosis as well as age-matched healthy control subjects with magnetic resonance spectroscopy (MRS).
Methods The subjects were 46 patients with first-episode psychosis (20 with a schizophrenia spectrum disorder, 26 with bipolar disorder) and 50 age-matched healthy control subjects. Glu and Gly levels were measured in vivo in the anterior cingulate cortex and posterior cingulate cortex of the subjects by using the echo time–averaged proton MRS technique at 4T (i.e., modified point resolved spectroscopy sequence: 24 echo time steps with 20-ms increments). Metabolite levels were quantified using LCModel with simulated basis sets.
Results Significantly higher Glu and Gly levels were found in both the anterior cingulate cortex and posterior cingulate cortex of patients with first-episode psychosis as compared with healthy control subjects. Glu and Gly levels were positively correlated in patients. Patients with a schizophrenia spectrum disorder and bipolar disorder showed similar abnormalities.
Conclusions Our findings demonstrate abnormally elevated brain Glu and Gly levels in patients with first-episode psychosis by means of echo time–averaged proton MRS at 4T. The findings implicate dysfunction of N-methyl-D-aspartate receptor and glutamatergic neurotransmission in the pathophysiology of the acute early phase of psychotic illnesses.
“In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time–Averaged Proton Magnetic Resonance Spectroscopy at 4T” by Sang-Young Kim, Marc J. Kaufman, Bruce M. Cohen, J. Eric Jensen, Joseph T. Coyle, Fei Du, and Dost Öngür in Biological Psychiatry. Published online September 7 2017 doi:10.1016/j.biopsych.2017.08.022